High risk of relapse with intermediate dose cytarabine for consolidation in young favourable‐risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature-Reference-Cited by-同舟云学术

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable‐risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Published:2021-04-11 Issue:1 Volume:194 Page:140-144
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Kolla Bhaskar C.¹^ORCID,Halim Nurul A. A.²,Cao Qing³,Sachs Zohar¹^ORCID,Warlick Erica¹,Weisdorf Daniel¹^ORCID,Ho Aloysius Y. L.²,Chuan Wong G.²,Lao Zhentang²,He Fiona¹

Affiliation:

1. Division of Hematology, Oncology, Blood and Marrow Transplantation University of Minnesota Minneapolis USA

2. Department of Haematology Singapore General Hospital Singapore Singapore

3. Biostatistics, Clinical and Translational Science Institute University of Minnesota Minneapolis USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17462

Reference14 articles.

1. Acute Myeloid Leukemia

2. Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

3. Frequency of prolonged remission duration after high‐dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype;Bloomfield CD;Cancer Res,1998

4. Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

5. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients;Holistic Integrative Oncology;2024-05-21

2. The Outcome of Outpatient Intermediate and High Dose Cytarabine Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia;Journal of Stem Cell Therapy and Transplantation;2024-05-09

3. Optimal Post-Remission Consolidation Therapy in Patients with AML;Acta Haematologica;2023-11-26

4. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia;Hematology;2023-07-05

5. How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines;Blood;2023-02-09